Highest-materiality recent filing
Merck shareholders elect all 13 directors, approve say-on-pay, reject three proposals
All 13 director nominees elected; Patricia Russo received 1.637B for (highest opposition at 217M votes against).
Merck closes $6B multi-tranche debt offering with maturities from 2028 to 2056
Issued $6B aggregate principal across seven tranches: floating rate notes due 2028 and fixed-rate notes at 4.300%-5.850% due 2028-2056.
Merck reports Q1 GAAP loss per share of $1.72 on $16.3B sales; narrows and raises full-year guidance
GAAP EPS loss of $1.72; Non-GAAP EPS loss of $1.28, both include $3.62/share charge for Cidara acquisition.
Merck Q4 Non-GAAP EPS $2.04 (+19% YoY); FY2026 guidance $5.00-$5.15 on Cidara charge
Q4 2025 sales $16.4B (+5% GAAP EPS $1.19, Non-GAAP EPS $2.04).
Merck closes $8.0B multi-tranche debt offering across eight series
Total $8.0B includes Floating Rate Notes due 2029 ($500M), 3.850% Notes due 2029 ($750M), 4.150% due 2031 ($1B), 4.450% due 2032 ($1B).
Merck Q3 GAAP EPS $2.32, non-GAAP $2.58; raises full-year non-GAAP EPS guidance to $8.93-8.98
Total sales $17.3B (+4% YoY, +3% ex-FX); GAAP net income $5.8B, non-GAAP $6.4B.
Merck closes $6B multi-tranche debt offering: floating-rate notes due 2027 to 5.700% notes due 2055
Offered $500M floating rate notes due 2027, $750M 3.850% notes due 2027, $750M 4.150% notes due 2030.
Merck reports Q2 2025 sales of $15.8B, down 2%, and announces $3B restructuring program
Total worldwide sales $15.8 billion, down 2% nominally and ex-forex vs Q2 2024; KEYTRUDA sales $8.0 billion, up 9%.
All 13 director nominees elected; Patricia Russo received lowest support with 1.59B for and 250.6M against.
Merck reports Q1 2025 EPS $2.01, sales $15.5B; GARDASIL plunges 41% on China weakness
GAAP EPS $2.01 (up 7% YoY); non-GAAP EPS $2.22 (up 7%); revenue $15.5B (-2% reported, +1% ex-FX).
Merck Q4 2024 sales $15.6B (+7% YoY); GAAP EPS $1.48, Non-GAAP $1.72; FY2025 guidance issued
Full-year 2024 worldwide sales $64.2B (+7% YoY; +10% ex-FX).
Lal Karsanbhai (Emerson CEO) elected to Merck board; effective Jan 1, 2025
Lal Karsanbhai, president and CEO of Emerson Electric, elected to Merck board effective January 1, 2025.
Merck Q3 2024: GAAP EPS $1.24, Non-GAAP $1.57; Sales $16.7B (+4% YoY)
Total worldwide sales $16.7B, up 4% (7% ex-FX). GAAP EPS $1.24; Non-GAAP EPS $1.57.
Q2 revenue $16.1B (+7% YoY, +11% ex-FX); GAAP EPS $2.14, Non-GAAP EPS $2.28; KEYTRUDA sales $7.3B (+16%).
Merck subsidiary MSD Netherlands closes €3.4B offering of senior notes across four tranches
€850M each of 3.250% notes due 2032, 3.500% notes due 2037, 3.700% notes due 2044, 3.750% notes due 2054.
Merck Q1 sales up 9% to $15.8B; raises FY2024 sales and EPS guidance
GAAP EPS $1.87 (+68% YoY); Non-GAAP EPS $2.07 (+48% YoY). Sales $15.775B (+9%, +12% ex-FX).
announcing the election of Surendralal L. “Lal” Karsanbhai to the Company’s Board of Directors (the “Board”), effective January 1, 2025.
Max materiality 0.90 · Median 0.70 · Most common event earnings